行情

ACHV

ACHV

Achieve
NASDAQ

实时行情|Nasdaq Last Sale

6.95
-0.20
-2.80%
交易中 15:28 01/27 EST
开盘
7.28
昨收
7.15
最高
7.35
最低
6.82
成交量
4.31万
成交额
--
52周最高
16.10
52周最低
6.55
市值
6,570.21万
市盈率(TTM)
-1.4960
分时
5日
1月
3月
1年
5年
Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation
Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinicline dosed three times daily compared to placebo in 75...
Benzinga · 2天前
Achieve Life commences Phase 3 trial of cytisinicline for smoking cessation
Achieve Life Sciences (NASDAQ:ACHV) has initiated screening of ORCA-3, the confirmatory Phase 3 trial required for registrational approval of cytisinicline in U.S. ORCA-3 will evaluate the efficacy and safety of
Seekingalpha · 2天前
Achieve Life Sciences Announces Initiation Of The Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline For Smoking Cessation
Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced
Benzinga · 2天前
Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation
SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation ...
GlobeNewswire · 2天前
Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference
SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, to...
GlobeNewswire · 01/06 13:30
Achieve Life Sciences Announces Completion Of Last Subject, Last Follow-Up Visit In Phase 3 ORCA-2 Trial Of Cytisinicline For Smoking Cessation
Achieve Life Sciences, Inc.
Benzinga · 01/04 13:33
BRIEF-SVB Financial Group Reports 14.5% Passive Stake In Achieve Life Sciences
reuters.com · 2021/12/29 21:25
Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program
Achieve Life Sciences Inc (NASDAQ: ACHV) has 
Benzinga · 2021/12/22 17:16
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解ACHV最新的财务预测,通过ACHV每股收益,每股净资产,每股现金流等数据分析Achieve近期的经营情况,然后做出明智的投资选择。
分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

28.57%强力推荐
71.43%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测ACHV价格均价为31.50,最高价位58.00,最低价为20.00。
最高58.00
均价31.50
最低20.00
现价6.95
EPS
实际EPS
预期EPS
-1.22-0.92-0.61-0.31
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 47
机构持股: 244.14万
持股比例: 25.82%
总股本: 945.35万
类型机构数股数
增持
11
6.32万
建仓
8
12.30万
减持
9
17.14万
平仓
4
14.63万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-2.44%
制药与医学研究
+0.53%
高管信息
Chairman/Executive Director
Richard Stewart
President/Director
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Lead Director/Independent Director
Donald Joseph
Independent Director
Bridget Martell
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
暂无数据
ACHV 简况
Achieve Life Sciences Inc是一家处于临床阶段的制药公司。该公司从事用于戒烟和尼古丁成瘾的胞嘧啶碱的开发和商业化。该公司的候选产品cytisinicline是一种天然存在的植物性生物碱,来自Laburnum anagyroides植物的种子。Cytisinicline在结构上与尼古丁相似,具有激动和拮抗的作用机制。该产品有助于戒烟,或尼古丁成瘾,通过与大脑中的尼古丁受体相互作用,通过对尼古丁受体的激动作用降低尼古丁戒断症状的严重程度,并通过拮抗特性降低与尼古丁相关的奖赏和满足感。

微牛提供Achieve Life Sciences Inc(NASDAQ-ACHV)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的ACHV股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易ACHV股票基本功能。